Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Astrocytoma × Eflornithine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Adenomatous Polyposis Coli 2 Neoplasms 1 Melanoma 1 Glioma 1 Colonic Polyps 1 Breast Neoplasms 1 Brain Neoplasms 1 Astrocytoma 1

Interventions

Temozolomide 16 Radiotherapy 7 Flucytosine 6 vocimagene amiretrorepvec 5 Surgical Procedures, Operative 5 Lomustine 4 IL13-PE38 4 Corticotropin-Releasing Hormone 3 Chlorotoxin 3 Carmustine 3 Bevacizumab 3 vorasidenib 2 trametinib 2 tovorafenib 2 regorafenib 2 pembrolizumab 2 paclitaxel-Angiopep-2 conjugate 2 dabrafenib 2 Valacyclovir 2 Trabedersen 2 Radiation 2 OKN 007 2 Nivolumab 2 Drug Delivery Systems 2 Carboplatin 2 Cancer Vaccines 2 Adjuvants, Immunologic 2 trastuzumab deruxtecan 1 talampanel 1 selinexor 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02796261 2022-01-21

STELLAR

Orbus Therapeutics, Inc.

Phase 3 Unknown

Astrocytoma, Brain Neoplasms, Glioma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡